Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
-
Madariaga, Ainhoa (Universitat Autònoma de Barcelona)
;
Garg, Swati (University Health Network, Toronto, Canada) ;
Tchrakian, Nairi (University Health Network, Toronto, Canada) ;
Dhani, Neesha C. (University of Toronto, Canada) ;
Jimenez, Waldo (Juravinski Cancer Centre, Hamilton, Canada) ;
Welch, Stephen (London Health Sciences Center, London, Canada) ;
MacKay, Helen (Odette Cancer Centre. Sunnybrook Health Sciences Centre, Toronto, Canada) ;
Ethier, Josee-Lyne (Kingston Health Sciences Cancer Centre, Kingston, Canada) ;
Gilbert, Lucy (Royal Victoria Hospital, Montréal, Canada) ;
Li, Xuan (University Health Network, Toronto, Canada) ;
Rodriguez, Angela (University Health Network, Toronto, Canada) ;
Chan, Lucy (University Health Network, Toronto, Canada) ;
Bowering, Valerie (University Health Network, Toronto, Canada) ;
Clarke, Blaise (University Health Network, Toronto, Canada) ;
Zhang, Tong (University of Toronto, Canada) ;
King, Ian (University of Toronto, Canada) ;
Downs, Gregory (University of Toronto, Canada) ;
Stockley, Tracy (University of Toronto, Canada) ;
Wang, Lisa (University of Toronto, Toronto, Canada) ;
Udagani, Smitha (University Health Network, Toronto, Canada) ;
Oza, Amit M. (University of Toronto, Canada) ;
Lheureux, Stephanie (University of Toronto, Canada)
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
